The efficacy of low-dose warfarin initiation (3 mg versus 5 mg) in newly diagnosed venous thromboembolism patients among a population with a high prevalence of warfarin-sensitive haplotype of the VKORC1 gene: a randomized controlled trial

References

• Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:160S–198S. doi:10.1378/chest.08-0670.
   PubMed Web of Science ®Google Scholar
• Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med. 1999;159:46–48. doi:10.1001/archinte.159.1.46.
   PubMed Web of Science ®Google Scholar
• Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med. 1997;126:133–136. doi:10.7326/0003-4819-126-2-199701150-00006.
   PubMed Web of Science ®Google Scholar
• Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med. 2003;138:714–719. doi:10.7326/0003-4819-138-9-200305060-00007.
   PubMed Web of Science ®Google Scholar
• Geisen C, Watzka M, Sittinger K, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005;94:773–779.
   PubMed Web of Science ®Google Scholar
• D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105:645–649.
   PubMed Web of Science ®Google Scholar
• Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285–2293. doi:10.1056/NEJMoa044503.
   PubMed Web of Science ®Google Scholar
• Herman D, Peternel P, Stegnar M, et al. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost. 2006;95:782–787. doi:10.1160/TH05-10-0678.
   PubMed Web of Science ®Google Scholar
• Marsh S, King CR, Porche-Sorbet RM, et al. Population variation in VKORC1 haplotype structure. J Thromb Haemost. 2006;4:473–474. doi:10.1111/j.1538-7836.2006.01759.x.
   PubMed Web of Science ®Google Scholar
• Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005;39:1008–1012. doi:10.1345/aph.1E566.
   PubMed Web of Science ®Google Scholar
• Zhao F, Loke C, Rankin SC, et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004;76:210–219. doi:10.1016/j.clpt.2004.05.005.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Wilkinson GR, Caraco Y, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther. 2003;73:253–263. doi:10.1067/mcp.2003.26a.
   PubMed Web of Science ®Google Scholar
• Lee SC, Ng SS, Oldenburg J, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther. 2006;79:197–205. doi:10.1016/j.clpt.2005.11.006.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics. 2006;16:101–110. doi:10.1097/01.fpc.0000184955.08453.a8.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102:397–404. doi:10.1002/cpt.668.
   PubMed Web of Science ®Google Scholar
• Abbas SSU, Bhatti S, Naqi A, et al. Interethnic diversity of CYP2C9 alleles on pharmacogenetics in healthy Sindhi and Baluchi population samples: correlation to global allelic frequencies scientific reports. 2012;1:520. doi:10.4172/scientificreports.520.
   Google Scholar
• Xie HG, Prasad HC, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002;54:1257–1270. doi:10.1016/S0169-409X(02)00076-5.
   PubMed Web of Science ®Google Scholar
• Owen RP, Gong L, Sagreiya H, et al. VKORC1. Pharmacogenet Genomics. 2010;20:642–644. doi:10.1097/FPC.0b013e32833433b6.
   PubMed Web of Science ®Google Scholar
• Suwanawiboon B, Kongtim P, Chinthammitr Y, et al. The efficacy of 3-mg warfarin initiating dose in adult Thai patients, who required long-term anticoagulant therapy. J Med Assoc Thai. 2011;94(Suppl 1):S225–S231.
   PubMedGoogle Scholar
• Moyer TP, O'Kane DJ, Baudhuin LM, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc. 2009;84:1079–1094. doi:10.4065/mcp.2009.0278.
   PubMed Web of Science ®Google Scholar
• Klamchuen S CA, Angchaisuksiri P, Sasanakul W. Frequency of polymorphisms associated with VKORC1 gene in Thai blood donors and patients receiving warfarin. J Hematol Transf Med. 2008;18:307–313.
   Google Scholar
• Sermsathanasawadi N, Sritongsathian C, Pongrattanaman N, et al. The influence of VKORC1 polymorphisms on warfarin doses in Thai patients with deep vein thrombosis. J Med Assoc Thai. 2015;98:549–554.
   PubMedGoogle Scholar
• Kuanprasert S, Dettrairat S, Palacajornsuk P, et al. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand. J Med Assoc Thai. 2009;92:1597–1601.
   PubMedGoogle Scholar
• Sangviroon A, Panomvana D, Tassaneeyakul W, et al. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin. Drug Metab Pharmacokinet. 2010;25:531–538. doi:10.2133/dmpk.DMPK-10-RG-059.
   PubMed Web of Science ®Google Scholar